1.The first reported hepatitis E outbreak in a food manufacturing factory: Korea, 2022
Hansol YEOM ; Soonryu SEO ; Youngsil YOON ; Jaeeun LEE ; Myung-Guk HAN ; Deog-Yong LEE ; Sun-Whan PARK ; Song A PARK ; Sook-Hyang JEONG ; Jin GWACK
Osong Public Health and Research Perspectives 2023;14(1):15-22
Objectives:
On February 16, 2022, 12 cases of hepatitis E virus (HEV) infection were reported in a food manufacturing factory in Korea. The aim of this study was to identify additional cases and to determine the source of this HEV outbreak.
Methods:
This study was an in-depth investigation of 12 HEV immunoglobulin M (IgM)-positive cases and their demographic, clinical, and epidemiological characteristics. On-site specimens were collected from the environment and from humans, and a follow-up investigation was conducted 2 to 3 months after the outbreak.
Results:
Among 80 production workers in the factory, 12 (15.0%) had acute HEV infection, all of whom were asymptomatic. The follow-up investigation showed that 3 cases were HEV IgM-positive, while 6 were HEV IgG-positive. HEV genes were not detected in the HEV IgM-positive specimens. HEV genes were not detected in the food products or environmental specimens collected on-site. HEV was presumed to be the causative pathogen. However, it could not be confirmed that the source of infection was common consumption inside the factory.
Conclusion
This was the first domestic case of an HEV infection outbreak in a food manufacturing factory in Korea. Our results provide information for the future control of outbreaks and for the preparation of measures to prevent domestic outbreaks of HEV infection.
2.Two Cases of Herpes Zoster Following Varicella Vaccination in Immunocompetent Young Children:One Case Caused by Vaccine-Strain
Da-Eun KIM ; Hae Ji KANG ; Myung-Guk HAN ; Hye-young YEOM ; Sung Hee CHANG
Pediatric Infection & Vaccine 2022;29(2):110-117
Herpes zoster (HZ) has been reported in immunocompetent children who received the varicella vaccine. In vaccinated children, HZ can be caused by vaccine-strain or by wild-type varicella-zoster virus (VZV). Like wild-type VZV, varicella vaccine virus can establish latency and reactivate as HZ. We report two cases of HZ in otherwise healthy 16- and 14-month-old boys who received varicella vaccine at 12 months of age. They presented with a vesicular rash on their upper extremities three to four months after varicella vaccination. In one case, a swab was obtained by abrading skin vesicles and VZV was detected in skin specimens by polymerase chain reaction. The VZV open-reading frame 62 was sequenced and single nucleotide polymorphism analysis confirmed that the virus from skin specimen was vaccinestrain. This is the first HZ case following varicella vaccination confirmed to be caused by vaccine-strain VZV in the immunocompetent children in Korea. Pediatricians should be aware of the potential for varicella vaccine virus reactivation in vaccinated young children.
3.Erratum: COVID-19 Molecular Testing in Korea:Practical Essentials and Answers From Experts Based on Experiences of Emergency Use Authorization Assays
Heungsup SUNG ; Kyoung Ho ROH ; Ki Ho HONG ; Moon-Woo SEONG ; Namhee RYOO ; Hyun Soo KIM ; Jaehyeon LEE ; So Yeon KIM ; Sook Won RYU ; Mi-Na KIM ; Myung Guk HAN ; Sang Won LEE ; Hyukmin LEE ; Cheon Kwon YOO ;
Annals of Laboratory Medicine 2021;41(1):126-127
4.Genomic Surveillance of SARS-CoV-2: Distribution of Clades in the Republic of Korea in 2020
Ae Kyung PARK ; Il-Hwan KIM ; Junyoung KIM ; Jeong-Min KIM ; Heui Man KIM ; Chae young LEE ; Myung-Guk HAN ; Gi-Eun RHIE ; Donghyok KWON ; Jeong-Gu NAM ; Young-Joon PARK ; Jin GWACK ; Nam-Joo LEE ; SangHee WOO ; Jin Sun NO ; Jaehee LEE ; Jeemin HA ; JeeEun RHEE ; Cheon-Kwon YOO ; Eun-Jin KIM
Osong Public Health and Research Perspectives 2021;12(1):37-43
Since a novel beta-coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in December 2019, there has been a rapid global spread of the virus. Genomic surveillance was conducted on samples isolated from infected individuals to monitor the spread of genetic variants of SARS-CoV-2 in Korea. The Korea Disease Control and Prevention Agency performed whole genome sequencing of SARS-CoV-2 in Korea for 1 year (January 2020 to January 2021). A total of 2,488 SARSCoV-2 cases were sequenced (including 648 cases from abroad). Initially, the prevalent clades of SARSCoV-2 were the S and V clades, however, by March 2020, GH clade was the most dominant. Only international travelers were identified as having G or GR clades, and since the first variant 501Y.V1 was identified (from a traveler from the United Kingdom on December 22 nd , 2020), a total of 27 variants of 501Y.V1, 501Y.V2, and 484K.V2 have been classified (as of January 25 th , 2021). The results in this study indicated that quarantining of travelers entering Korea successfully prevented dissemination of the SARS-CoV-2 variants in Korea.
5.The laboratory test procedure to confirm rotavirus vaccine infection in severe complex immunodeficiency patients
Su-Jin CHAE ; Seung-Rye CHO ; Wooyoung CHOI ; Myung-Guk HAN ; Deog-Yong LEE
Osong Public Health and Research Perspectives 2021;12(4):269-273
The rotavirus vaccine is a live vaccine, and there is a possibility of infection by the virus strain used in the vaccine. We investigated the process of determining whether an infection was caused by the vaccine strain in a severe complex immunodeficiency (SCID) patient with rotavirus infection. The patient was vaccinated with RotaTeq prior to being diagnosed with SCID. The testing process was conducted in the following order: confirming rotavirus infection, determining its genotype, and confirming the vaccine strain. Rotavirus infection was confirmed through enzyme immunoassay and VP6 gene detection. G1 and P[8] were identified by multiplex polymerase chain reaction for the genotype, and G3 was further identified using a single primer. By detecting the fingerprint gene (WC3) of RotaTeq, it was confirmed that the detected virus was the vaccine strain. Genotypes G1 and P[8] were identified, and the infection was suspected of having been caused by rotavirus G1P[8]. G1P[8] is the most commonly detected genotype worldwide and is not included in the recombinant strains used in vaccines. Therefore, the infection was confirmed to have been caused by the vaccine strain by analyzing the genetic relationship between VP4 and VP7. Rotavirus infection by the vaccine strain can be identified through genotyping and fingerprint gene detection. However, genetic linkage analysis will also help to identify vaccine strains.
6.The laboratory test procedure to confirm rotavirus vaccine infection in severe complex immunodeficiency patients
Su-Jin CHAE ; Seung-Rye CHO ; Wooyoung CHOI ; Myung-Guk HAN ; Deog-Yong LEE
Osong Public Health and Research Perspectives 2021;12(4):269-273
The rotavirus vaccine is a live vaccine, and there is a possibility of infection by the virus strain used in the vaccine. We investigated the process of determining whether an infection was caused by the vaccine strain in a severe complex immunodeficiency (SCID) patient with rotavirus infection. The patient was vaccinated with RotaTeq prior to being diagnosed with SCID. The testing process was conducted in the following order: confirming rotavirus infection, determining its genotype, and confirming the vaccine strain. Rotavirus infection was confirmed through enzyme immunoassay and VP6 gene detection. G1 and P[8] were identified by multiplex polymerase chain reaction for the genotype, and G3 was further identified using a single primer. By detecting the fingerprint gene (WC3) of RotaTeq, it was confirmed that the detected virus was the vaccine strain. Genotypes G1 and P[8] were identified, and the infection was suspected of having been caused by rotavirus G1P[8]. G1P[8] is the most commonly detected genotype worldwide and is not included in the recombinant strains used in vaccines. Therefore, the infection was confirmed to have been caused by the vaccine strain by analyzing the genetic relationship between VP4 and VP7. Rotavirus infection by the vaccine strain can be identified through genotyping and fingerprint gene detection. However, genetic linkage analysis will also help to identify vaccine strains.
7.Viral Load Kinetics of SARS-CoV-2 Infection in First Two Patients in Korea
Jin Yong KIM ; Jae Hoon KO ; Yeonjae KIM ; Yae Jean KIM ; Jeong Min KIM ; Yoon Seok CHUNG ; Heui Man KIM ; Myung Guk HAN ; So Yeon KIM ; Bum Sik CHIN
Journal of Korean Medical Science 2020;35(7):86-
As of February 2020, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak started in China in December 2019 has been spreading in many countries in the world. With the numbers of confirmed cases are increasing, information on the epidemiologic investigation and clinical manifestation have been accumulated. However, data on viral load kinetics in confirmed cases are lacking. Here, we present the viral load kinetics of the first two confirmed patients with mild to moderate illnesses in Korea in whom distinct viral load kinetics are shown. This report suggests that viral load kinetics of SARS-CoV-2 may be different from that of previously reported other coronavirus infections such as SARS-CoV.
China
;
Coronavirus
;
Coronavirus Infections
;
Humans
;
Kinetics
;
Korea
;
SARS Virus
;
Severe Acute Respiratory Syndrome
;
Viral Load
8.Survival Trend of HIV/AIDS Patients Starting Antiretroviral Therapy in South Korea between 2001 and 2015
Yong Chan KIM ; Jin Young AHN ; Hyo Youl KIM ; Joon Young SONG ; Dae Won PARK ; Min Ja KIM ; Hee-Jung CHOI ; Shin Woo KIM ; Mee-Kyung KEE ; Myung Guk HAN ; Myeongsu YOO ; Soo Min KIM ; Yunsu CHOI ; Bo Youl CHOI ; Sang Il KIM ; Jun Yong CHOI
Yonsei Medical Journal 2020;61(8):705-711
Purpose:
In the recent antiretroviral therapy (ART) era, a large proportion of Korean patients with human immunodeficiency virus (HIV) infection were shown to have low CD4 cell counts at diagnosis and during ART initiation. We investigated the survival trends in patients living with HIV/acquired immunodeficiency syndrome (AIDS) in Korea who started ART in the 2000s, and evaluated the risk factors for mortality to elucidate the association between survival and low CD4 cell counts at ART initiation.
Materials and Methods:
Patients with HIV infection who were aged >18 years and had started ART between 2001 and 2015 in the Korean HIV/AIDS cohort study were enrolled. We compared the clinical characteristics, mortality, and causes of death among the enrolled subjects based on the time of ART initiation. Cox regression analysis was used to estimate the adjusted hazard ratios of mortality based on the time of ART initiation.
Results:
Among the 2474 patients enrolled, 105 (4.24%) died during the follow-up period of 9568 patient-years. Although CD4 cell counts at the time of ART initiation significantly increased from 161 [interquartile range (IQR), 73.5–303] in 2001–2003 to 273 (IQR, 108–399) in 2013–2015 (p<0.001), they remained low during the study period. The incidence of all-cause mortality was 10.97 per 1000 patient-years during the study period. There was no decreasing trend in mortality between 2001 and 2015. Age >40 years [adjusted hazard ratio, 3.71; 95% confidence interval (CI), 2.35–5.84] and low CD4 counts (<100 cells/mm3: adjusted hazard ratio, 2.99; 95% CI, 1.44–6.23) were significant risk factors for mortality.
Conclusion
Despite excellent HIV care available in the recent ART era, the survival of patients with HIV/AIDS undergoing ART did not improve between 2001 and 2015 in Korea.
9.Identification of Coronavirus Isolated from a Patient in Korea with COVID-19
Jeong-Min KIM ; Yoon-Seok CHUNG ; Hye Jun JO ; Nam-Joo LEE ; Mi Seon KIM ; Sang Hee WOO ; Sehee PARK ; Jee Woong KIM ; Heui Man KIM ; Myung-Guk HAN
Osong Public Health and Research Perspectives 2020;11(1):3-7
Following reports of patients with unexplained pneumonia at the end of December 2019 in Wuhan, China, the causative agent was identified as coronavirus (SARS-CoV-2), and the 2019 novel coronavirus disease was named COVID-19 by the World Health Organization. Putative patients with COVID-19 have been identified in South Korea, and attempts have been made to isolate the pathogen from these patients. Upper and lower respiratory tract secretion samples from putative patients with COVID-19 were inoculated onto cells to isolate the virus. Full genome sequencing and electron microscopy were used to identify the virus. The virus replicated in Vero cells and cytopathic effects were observed. Full genome sequencing showed that the virus genome exhibited sequence homology of more than 99.9% with SARS-CoV-2 which was isolated from patients from other countries, for instance China. Sequence homology of SARS-CoV-2 with SARS-CoV, and MERS-CoV was 77.5% and 50%, respectively. Coronavirus-specific morphology was observed by electron microscopy in virus-infected Vero cells. SARS-CoV-2 was isolated from putative patients with unexplained pneumonia and intermittent coughing and fever. The isolated virus was named BetaCoV/Korea/KCDC03/2020.
10.2019 Tabletop Exercise for Laboratory Diagnosis and Analyses of Unknown Disease Outbreaks by the Korea Centers for Disease Control and Prevention
Il-Hwan KIM ; Jun Hyeong JANG ; Su-Kyoung JO ; Jin Sun NO ; Seung-Hee SEO ; Jun-Young KIM ; Sang-Oun JUNG ; Jeong-Min KIM ; Sang-Eun LEE ; Hye-Kyung PARK ; Eun-Jin KIM ; Jun Ho JEON ; Myung-Min CHOI ; Bo yeong RYU ; Yoon Suk JANG ; Hwa mi KIM ; Jin LEE ; Seung-Hwan SHIN ; Hee Kyoung KIM ; Eun-Kyoung KIM ; Ye Eun PARK ; Cheon-Kwon YOO ; Sang-Won LEE ; Myung-Guk HAN ; Gi-Eun RHIE ; Byung Hak KANG
Osong Public Health and Research Perspectives 2020;11(5):280-285
Objectives:
The Korea Centers for Disease Control and Prevention has published “A Guideline for Unknown Disease Outbreaks (UDO).” The aim of this report was to introduce tabletop exercises (TTX) to prepare for UDO in the future.
Methods:
The UDO Laboratory Analyses Task Force in Korea Centers for Disease Control and Prevention in April 2018, assigned unknown diseases into 5 syndromes, designed an algorithm for diagnosis, and made a panel list for diagnosis by exclusion. Using the guidelines and laboratory analyses for UDO, TTX were introduced.
Results:
Since September 9th , 2018, the UDO Laboratory Analyses Task Force has been preparing TTX based on a scenario of an outbreak caused by a novel coronavirus. In December 2019, through TTX, individual missions, epidemiological investigations, sample treatments, diagnosis by exclusions, and next generation sequencing analysis were discussed, and a novel coronavirus was identified as the causal pathogen.
Conclusion
Guideline and laboratory analyses for UDO successfully applied in TTX. Conclusions drawn from TTX could be applied effectively in the analyses for the initial response to COVID-19, an ongoing epidemic of 2019 - 2020. Therefore, TTX should continuously be conducted for the response and preparation against UDO.

Result Analysis
Print
Save
E-mail